Dr. Harshini Neelakantan
Biography & Research Background
Harshini Neelakantan, PhD, served as lead scientist at UTMB and is now Executive Director of R&D at Ridgeline Therapeutics. She is co-inventor of 5-Amino 1MQ and led the seminal in vitro and in vivo experiments including the structure-activity relationship study (J. Med. Chem. 2017), the landmark obesity reversal paper (Biochem. Pharmacol. 2018), the muscle stem cell activation study (2019), and the pharmacokinetic characterization (J. Pharm. Biomed. Anal. 2021). Harshini Neelakantan is being referenced as one of the leading scientists involved in the research and development of 5-Amino-1MQ. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
External Profiles
Authored Research Profiles (1)
Dr. Harshini Neelakantan is referenced as a leading researcher in the following peptide research profiles on Pure U.S. Peptides:
Dr. Harshini Neelakantan is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure U.S. Peptides and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.